

## Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment

Allison W. Kurian, Emily E. Hare, Meredith A. Mills, Kerry E. Kingham, Lisa McPherson, Alice S. Whittemore, Valerie McGuire, Uri Ladabaum, Yuya Kobayashi, Stephen E. Lincoln, Michele Cargill, and James M. Ford

See accompanying editorial on page 1987

Allison W. Kurian, Meredith A. Mills, Kerry E. Kingham, Lisa McPherson, Alice S. Whittemore, Valerie McGuire, Uri Ladabaum, James M. Ford, Stanford University School of Medicine, Stanford; Emily E. Hare, Yuya Kobayashi, Stephen E. Lincoln, Michele Cargill, InVita, San Francisco, CA.

Published online ahead of print at [www.jco.org](http://www.jco.org) on April 14, 2014.



Processed as a Rapid Communication manuscript.

Supported by the Breast Cancer Research Foundation, a Stanford University Cancer Institute Developmental Research Award, the Jan Weimer Junior Faculty Chair in Breast Oncology at Stanford University, National Institutes of Health Clinical and Translational Science Award No. UL1 RR025744, and InVita.

Presented in part at the American Society of Clinical Oncology Breast Cancer Symposium, San Francisco, CA, September 7-9, 2013, and at the American Society of Human Genetics Annual Meeting, Boston, MA, October 22-26, 2013.

Terms in [blue](#) are defined in the glossary, found at the end of this article and online at [www.jco.org](http://www.jco.org).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Corresponding author: James M. Ford, MD, Associate Professor of Medicine, Pediatrics and Genetics, Division of Oncology, Stanford University School of Medicine, CCSR Building, Room 1115, 269 Campus Dr, Stanford CA, 94305; e-mail: [jmf@stanford.edu](mailto:jmf@stanford.edu).

© 2014 by American Society of Clinical Oncology

0732-183X/14/3219w-2001w/\$20.00

DOI: 10.1200/JCO.2013.53.6607

### ABSTRACT

#### Purpose

Multiple-gene sequencing is entering practice, but its clinical value is unknown. We evaluated the performance of a customized germline-DNA sequencing panel for cancer-risk assessment in a representative clinical sample.

#### Methods

Patients referred for clinical *BRCA1/2* testing from 2002 to 2012 were invited to donate a research blood sample. Samples were frozen at  $-80^{\circ}\text{C}$ , and DNA was extracted from them after 1 to 10 years. The entire coding region, exon-intron boundaries, and all known pathogenic variants in other regions were sequenced for 42 genes that had cancer risk associations. Potentially actionable results were disclosed to participants.

#### Results

In total, 198 women participated in the study: 174 had breast cancer and 57 carried germline *BRCA1/2* mutations. *BRCA1/2* analysis was fully concordant with prior testing. Sixteen pathogenic variants were identified in *ATM*, *BLM*, *CDH1*, *CDKN2A*, *MUTYH*, *MLH1*, *NBN*, *PRSS1*, and *SLX4* among 141 women without *BRCA1/2* mutations. Fourteen participants carried 15 pathogenic variants, warranting a possible change in care; they were invited for targeted screening recommendations, enabling early detection and removal of a tubular adenoma by colonoscopy. Participants carried an average of 2.1 variants of uncertain significance among 42 genes.

#### Conclusion

Among women testing negative for *BRCA1/2* mutations, multiple-gene sequencing identified 16 potentially pathogenic mutations in other genes (11.4%; 95% CI, 7.0% to 17.7%), of which 15 (10.6%; 95% CI, 6.5% to 16.9%) prompted consideration of a change in care, enabling early detection of a precancerous colon polyp. Additional studies are required to quantify the penetrance of identified mutations and determine clinical utility. However, these results suggest that multiple-gene sequencing may benefit appropriately selected patients.

*J Clin Oncol* 32:2001-2009. © 2014 by American Society of Clinical Oncology

### INTRODUCTION

Clinical genetic testing for cancer-risk assessment has become widespread over the last two decades, with evidence-based testing guidelines for hereditary breast and ovarian cancer (*BRCA1* and *BRCA2*; *BRCA1/2*), Lynch syndrome (*MLH1*, *MSH2*, *MSH6*, *PMS2*, and *EPCAM*), familial adenomatous polyposis (*APC*), hereditary diffuse gastric cancer (*CDH1*), Li-Fraumeni syndrome (*TP53*), Cowden's syndrome (*PTEN*), and a few other conditions.<sup>1-4</sup> Cancer genetic counseling and risk-reducing interventions have accordingly been developed for high penetrance, autosomal dominant conditions. Most of these interventions, especially prophylactic surgery, are excessive for carriers of mutations that

have uncertain pathogenicity.<sup>5-7</sup> Recently, next-generation technology has enabled massively parallel sequencing at low cost, and panels of multiple cancer-associated genes are newly available for clinical use.<sup>8,9</sup>

Despite these advances in technology, a critical knowledge deficit remains about the clinical value of multiple-gene panels for cancer susceptibility. Major questions include how many and which genes to sequence, whether results are sufficiently understood to guide intervention, and how best to counsel patients about variants of low or moderate penetrance.<sup>8,10-12</sup> We designed a customized germline sequencing panel of 42 cancer-associated genes and evaluated its information yield among women referred for clinical evaluation of hereditary breast

and ovarian cancer. Specifically, we aimed to assess the concordance of results with prior clinical sequencing, the prevalence of potentially actionable results, and the downstream effects on cancer screening and risk-reduction.

## METHODS

### Participant Accrual

Patients were eligible to participate if they were female, at least 18 years old, and had undergone clinical *BRCA1/2* testing at the Stanford University Clinical Cancer Genetics program from 2002 to 2012. The criteria for clinical genetic counseling and *BRCA1/2* testing were those accepted by insurance carriers, based on guidelines of the National Comprehensive Cancer Network at the time of evaluation. Some patients had a personal history of breast and/or ovarian cancer; some had a family history of breast, ovarian, pancreatic, and/or prostate cancers; and some had both personal and family history of such cancers.<sup>2,3</sup> Since 2002, all patients undergoing clinical *BRCA1/2* testing (for an identified familial mutation; the Ashkenazi Jewish three-founder mutations panel; full sequencing with analysis of five common *BRCA1* rearrangements; and/or full sequencing with comprehensive rearrangement analysis, depending on the indication and year) were offered participation in a study approved by the Stanford University institutional review board (IRB). Patients were informed that participation would consist of donating two 5-mL tubes of blood for clinical *BRCA1/2* testing and that they might be contacted about participation in future research. Blood specimens were frozen at  $-80^{\circ}\text{C}$  and were linked to demographic, clinical, and genetic data stored in a secure research database.<sup>13-15</sup>

### Gene Selection

Genes were selected through a review of published literature. Most genes had a reported breast cancer association but some were associated with other cancer syndromes or DNA repair pathways, rendering a breast cancer–risk association plausible (Table 1).

### Sequencing

Sequencing was performed at InVita (San Francisco, CA), a clinical laboratory improvement amendments (CLIA) –approved laboratory. Two micrograms of genomic DNA per patient were sheared on a Covaris E220 sonicator (Woburn, MA) to 250 base pair (bp) mean fragment size. Genomic DNA was quantified and assessed for quality using the Life Technologies Quant-iT PicoGreen double-strand DNA assay kit (Carlsbad, CA). The entire coding region, exon-intron boundaries ( $\pm 10$  bp), and other regions containing known pathogenic variants were targeted and captured using Agilent SureSelect custom RNA probes (Santa Clara, CA) and Integrated DNA Technologies xGen Lockdown custom DNA probes (Coral, IL). Sequencing libraries were constructed using the Agilent SureSelectXT protocol and were quantified with the KAPA Biosystems Library Quantification Kit (Woburn, MA). These steps were performed in an automated fashion using the Agilent Bravo automated liquid-handling platform. Quantified libraries were sequenced on the Illumina MiSeq platform (San Diego, CA) using the  $2 \times 151$  bp configuration to at least  $400\times$  average coverage. Bioinformatics and data quality control followed the Genome Analysis Toolkit best-practices (Broad Institute, Cambridge, MA), with additional algorithms to detect larger insertions, deletions, and duplications.<sup>53</sup> *PMS2* exons 12 to 15 were excluded from analysis because of high homology to the known pseudogene. Deletion/duplication data were not available for 54 samples sequenced before the development of calibration standards used by the algorithm.

### Variant Classification

Sequence variants and large insertions and deletions were classified according to the American College of Medical Genetics (ACMG) guidelines for variant interpretation.<sup>54</sup> Variants were classified as pathogenic or likely pathogenic (collectively termed, pathogenic) if they conferred a truncating, initiation codon or splice donor/acceptor effect, if functional data demonstrated an effect on protein function relevant to disease phenotype, or if pathogenicity was otherwise demonstrated in published literature. If no functional data were

**Table 1.** Sequenced Genes and Criteria for Their Inclusion

Fully Sequenced Genes (n = 42)	Breast Cancer Relative Risk (or other inclusion criterion)	References
<i>APC</i>	Unknown (causes Familial Adenomatous Polyposis)	Redston et al <sup>16</sup>
<i>ATM</i>	1.5-3.8	Renwick et al <sup>17</sup>
<i>BLM</i>	1.2-3.3	Broberg et al <sup>18</sup>
<i>BMPR1A</i>	1.3	Saetrom et al <sup>19</sup>
<i>BRCA1</i>	4.0-7.0	Chen et al <sup>20</sup>
<i>BRCA2</i>	4.0-7.0	Chen et al <sup>21</sup>
<i>BRIP1</i>	1.2-3.2	Seal et al <sup>22</sup>
<i>CDH1</i>	5.9-7.3	Kaurah et al, <sup>23</sup> Pharoah et al <sup>24</sup>
<i>CDK4</i>	Unknown (functions as DNA repair gene)	Dean et al <sup>25</sup>
<i>CDKN2A</i>	1.1-1.7	Debniak et al <sup>26</sup>
<i>EPCAM</i>	1.2-1.6	Jiang et al <sup>27</sup>
<i>FANCA</i>	0.9-1.0	Barroso et al <sup>28</sup>
<i>FANCB</i>	0.8-1.2	Barroso et al <sup>28</sup>
<i>FANCC</i>	1.0-1.4	Barroso et al <sup>28</sup>
<i>FANCD2</i>	1.1-1.7	Barroso et al <sup>28</sup>
<i>FANCE</i>	0.9-1.2	Barroso et al <sup>28</sup>
<i>FANCF</i>	0.9-1.4	Barroso et al <sup>28</sup>
<i>FANCG</i>	0.8-1.0	Barroso et al <sup>28</sup>
<i>FANCI</i>	0.8-1.1	Barroso et al <sup>28</sup>
<i>FANCL</i>	1.0-1.1	Barroso et al <sup>28</sup>
<i>LIG4</i>	0.4-1.0	Kuschel et al <sup>29</sup>
<i>MEN1</i>	Unknown (causes multiple endocrine neoplasia 1)	Lemmens et al <sup>30</sup>
<i>MET</i>	Unknown (associated with papillary renal cell carcinoma risk)	Neklason et al <sup>31</sup>
<i>MLH1</i>	0.2-2.0	Win et al <sup>32</sup>
<i>MSH2</i>	1.2-3.7	Win et al <sup>32</sup>
<i>MSH6</i>	0-13	Win et al <sup>32</sup>
<i>MUTYH</i>	1.0-3.4	Rennert et al <sup>33</sup>
<i>NBN</i>	1.4-6.6	Bogdanova et al, <sup>34</sup> Seemanová et al, <sup>35</sup> Zhang et al <sup>36</sup>
<i>PALB2</i>	1.4-3.9	Rahman et al <sup>37</sup>
<i>PALLD</i>	Unknown (associated with pancreatic cancer risk)	Pogue-Geile et al <sup>38</sup>
<i>PMS2</i>	Unknown (causes Lynch syndrome)	Win <sup>32</sup>
<i>PRSS1</i>	0.7-1.6	Wagner et al <sup>39</sup>
<i>PTCH1</i>	Unknown (associated with basal cell nevus syndrome and glioblastoma)	Lee et al <sup>40</sup>
<i>PTEN</i>	2.0-5.0	Pilarski et al, <sup>41</sup> Tan et al <sup>42</sup>
<i>RAD51C</i>	1.5-7.8	Meindl et al <sup>43</sup>
<i>RET</i>	Unknown (causes multiple endocrine neoplasia 2)	Machens et al <sup>44</sup>
<i>SLX4</i>	1.0-2.0	Landwehr et al, <sup>45</sup> Shah et al <sup>46</sup>
<i>SMAD4</i>	Unknown (mutated in breast tumors)	Tram et al <sup>47</sup>
<i>SPINK1</i>	Unknown (mutated in breast tumors)	Soon et al <sup>48</sup>
<i>STK11</i>	2.0-4.0	Hearle et al, <sup>49</sup> Lim et al <sup>50</sup>
<i>TP53</i>	4.3-9.3	Gonzalez et al <sup>51</sup>
<i>VHL</i>	Unknown (mutated in breast tumors)	Kong et al <sup>52</sup>

available, missense, silent, and intronic variants were classified as variants of uncertain significance (VUS), benign or likely benign based on allele frequency in the 1,000 Genomes Study,<sup>55</sup> dbSNP,<sup>56</sup> or the Exome Variant Server.<sup>57</sup> Also, published literature on *BRCA1/2* VUS was reviewed to classify those variants further as benign or likely benign following the ACMG guidelines. For pathogenic variants, we then reviewed published literature and practice guidelines to assign a clinical status of potentially actionable versus not actionable. We defined potentially actionable results as pathogenic variants that either cause recognized hereditary cancer syndromes, such as Lynch syndrome or hereditary diffuse gastric cancer,<sup>58</sup> or have a published association with a two-fold or greater relative risk of breast cancer compared with that of an average woman, under which circumstance guidelines recommend annual screening with breast magnetic resonance imaging (MRI) and mammograms.<sup>59-61</sup> Participants with potentially actionable results were contacted by telephone, were invited to a genetic counseling visit, and were offered a CLIA-approved test to confirm research findings. Cancer screening and prevention recommendations were consistent with clinical practice guidelines focused on the estimated magnitude of cancer risk, given the absence of gene-specific guidelines for many of the sequenced genes.<sup>2,59,60,62,63</sup> Participants were not notified about results that do not currently affect care recommendations, including absence of sequence abnormalities, pathogenic variants considered not actionable, or variants of uncertain significance.<sup>2,58,59,60,63</sup>

**Statistical Analysis**

Participant characteristics and sequencing results were tabulated, with descriptive statistics including medians, means, and standard deviations for continuous data and proportions with 95% CI for categorical data. Proportions were compared using the  $\chi^2$  statistic. All *P* values are two-tailed.

**RESULTS**

**Participant Characteristics**

From January 1, 2001 to June 30, 2013, 1,805 patients underwent clinical *BRCA1/2* testing in the Stanford Clinical Cancer Genetics program. Six hundred fifty-four patients (36.2%) donated a research blood sample during clinical testing. From 654 research samples, 198 were randomly selected for study participation; 174 participants had breast cancer, and 57 carried a *BRCA1/2* mutation. Participants were diverse in age and race/ethnicity and were generally representative of the clinical population from which they were recruited (Table 2).

**Pathogenic Variants in *BRCA1* and *BRCA2***

Before study enrollment, 57 participants were known to carry 59 pathogenic variants in *BRCA1/2* as determined by standard clinical testing (Myriad Genetics, Salt Lake City, UT). The remaining 141 participants had tested negative for *BRCA1/2* mutations. Fifty-seven of these 59 mutations in *BRCA1/2* were confirmed by the gene panel. Of the two others, one was detected but interpreted as a VUS because the information in the literature did not meet ACMG criteria for pathogenicity.<sup>54</sup> The other was a large insertion in one of the 54 samples for which del/dup analysis was not performed in the panel test. Considering the assays performed, *BRCA1/2* analysis was

**Table 2.** Characteristics of the Study Participants Compared With the Larger Clinical Source Population

Characteristic	Study Participants (n = 198)		<i>BRCA1/2</i> Test at Stanford, 2001-2013 (n = 1,805)	
	No. of Participants	%	No. of Participants	%
Age, years				
Median	48		46	
Race/ethnicity				
NH white, Ashkenazi Jew	7	3.5	102	5.6
NH white, not Ashkenazi Jew	140	70.7	1,205	66.7
NH black	3	1.5	30	1.7
NH Asian/Pacific Islander	39	19.7	292	16.2
Hispanic	7	3.5	92	5.1
Unknown/other race or ethnicity*	2	1.0	84	4.6
Personal history of breast cancer				
Unilateral	138	69.7	1,139	63.1
Bilateral†	36	18.1	139	7.7
Age at first breast cancer diagnosis, years				
Median	44		44	
Personal history of ovarian cancer‡	1	0.5	136	7.5
Age at ovarian cancer diagnosis, median	72		52	
Personal history of other cancer‡	18	9.1	175	9.7
Family history of breast cancer	148	74.7	1,285	71.2
Family history of ovarian cancer	52	26.3	444	24.6
<i>BRCA1</i> mutation§	35	17.7	213	11.8
<i>BRCA2</i> mutation	24	12.1	194	10.7
Year of first clinic visit				
Median	2008		2009	
Range	2005-2011		2001-2013	

Abbreviation: NH, non-Hispanic.

\*For comparison between study participants and source population, *P* = .01 ( $\chi^2$  two-tailed test).

†For comparison between study participants and source population, *P* < .001 ( $\chi^2$  two-tailed test).

‡Other cancers were nonmelanoma skin cancer (n = 6), endometrial cancer (n = 3), melanoma (n = 2), colon cancer (n = 1), leukemia (n = 1), lymphoma (n = 1), pancreatic cancer (n = 1), salivary gland cancer (n = 1), thyroid cancer (n = 1), and unknown primary cancer (n = 1).

§For comparison between study participants and source population, *P* = .02 ( $\chi^2$  two-tailed test).

**Table 3.** Pathogenic Variants in Genes Other Than *BRCA1* or *BRCA2*, With Participant Characteristics and Clinical Decisions (potentially actionable or not)

Study ID	Race/Ethnicity	Cancer Site/Subtype	Age at Diagnosis (years)	<i>BRCA1/2</i> Mutation	Affected Gene	Variant Name	Variant Effect	Protein Change	Family Cancer History*	Clinical Decision	Reference
LS221	NH white	Breast, bilateral: ER/PR+, HER2-	44, 55	None	<i>ATM</i>	NM_000051.3:c.1402_1403delAA	Frameshift	Lys468GlnfsX18	Breast (45); prostate (n = 3; 60s)	PA	Buzin et al <sup>64</sup>
LS294	NH white	Breast: ER-/PR-/HER2-; endometrial	35, 46	None	<i>MLH1</i>	NM_000249.3:c.2190delT	Frameshift	Pro731LeufsX52	Breast (70); neuroblastoma (10); ovary (55); pancreas (65)	PA	Rouleau et al <sup>65</sup>
LS305	Filipino	Breast: ER/PR+, HER2-	43	None	<i>PRSS1</i>	NM_002769.4:c.346C>T	Missense	Arg116Cys	Breast (n = 3; 30s-70s); lymphoma (74); prostate (65)	PA	Szmola and Sahin-Tóth <sup>66</sup>
LS306	NH white	Breast, bilateral: ER/PR+, HER2-	57, 63	None	<i>BLM</i>	NM_000057.2:c.3558 + 1G>T	Splice donor	Not applicable	Breast, ovary (40s); colon (n = 3; 40s-70s); prostate (70)	PA	Novel
LS324	Filipino	Breast, bilateral: ER/PR+, HER2-	47, 55	<i>BRCA1</i>	<i>MUTYH</i>	NM_001048171.1:c.892-2A>G	Splice acceptor	Not applicable	Breast (57); ovarian (47); prostate (70)	PA	Novel
LS347	NH white	No personal cancer history	None	None	<i>SLX4</i>	NM_032444.2:c.5233_5234delGC	Frameshift	Ala1745SerfsX32	Bladder (75); breast (n = 3; 40s); colon (85)	PA	Novel
LS358	NH white	No personal cancer history	None	None	<i>MUTYH</i>	NM_001048171.1:c.1145G>A	Missense	Gly382Asp	Breast (45); colon (n = 2; 45, 65); ovarian (60)	PA	Ali et al, <sup>67</sup> Eliason et al <sup>68</sup>
LS373	Hispanic	Breast: ER/PR+, HER2-	36	None	<i>CDKN2A</i>	NM_000077.4:c.146T>C	Missense	Ile49Thr	Lung (55); unknown primary	NA	Lai et al <sup>68</sup>
LS380	Hispanic	Breast, bilateral: ER/PR+, ER/PR-	27, 33	None	<i>MUTYH</i>	NM_001048171.1:c.694G>T	Missense	Val232Phe	Cervical (70); lung, larynx (65)	PA	Bai et al, <sup>70</sup> Sieber et al <sup>71</sup>
LS384	Japanese	Breast: ER/PR+, HER2-	48	None	<i>MUTYH</i>	NM_001048171.1:c.892-2A>G	Splice acceptor	Not applicable	Breast (40s); gastric (90); ovarian (40s)	PA	Novel
LS400	NH white	Breast: ER/PR+, HER2+	50	None	<i>NBN</i>	NM_002485.4:c.643C>T	Missense	Arg215Trp	Breast (70s); melanoma (49)	PA	Seemanová et al <sup>72</sup>
LS430	NH white	Breast: ER/PR+, HER2-	61	None	<i>SLX4</i>	NM_032444.2:c.5229insG	Frameshift	Gln1744AlafsX34	Breast (n = 3; 40s); colon (n = 2, 39, 73); melanoma (27)	PA	Novel
LS443	NH white	No personal cancer history	None	None	<i>CDH1; NBN</i>	NM_004360.3:c.532-18C>T; NM_002485.4:c.643C>T	Intronic; Missense	Not applicable; Arg215Trp	Breast (n = 4; 50s-70s); colon (70s); ovary (60s)	PA; PA	Seemanová et al, <sup>72</sup> Suriano et al <sup>73</sup>
LS456	NH white	Breast: ER/PR+, HER2-	49	None	<i>ATM</i>	NM_000051.3:c.7271T>G	Missense	Val2424Gly	Breast (n = 2; 40s-60s); colon (n = 2; 30s-40s); melanoma (n = 2; 40, 58)	PA	McConville et al, <sup>74</sup> Mltui et al <sup>75</sup>
LS462	NH white	Breast: ER/PR+, HER2-	42	None	<i>MUTYH</i>	NM_001048171.1:c.494A>G	Missense	Tyr165Cys	Breast (56); lung (54, 76); pancreas (44)	PA	Ali et al, <sup>67</sup> Eliason et al <sup>68</sup>

Abbreviations: +, positive; -, negative; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NA, not actionable; NH, non-Hispanic; PA, potentially actionable; PR, progesterone receptor.

\*Family history of cancer in first- and second-degree relatives; parenthetical information includes patient age/decade of diagnosis (for multiple affected relatives, the number affected is reported, eg, n = 3; followed by relatives' ages).

concordant with prior testing for 197 of 197 participants, and pathogenicity interpretation was concordant for 196 (99.5%) of 197 participants (95% CI, 96.9% to 100%).

### Pathogenic Variants in Other Genes

Sixteen pathogenic variants were detected in women who tested negative for *BRCA1/2* mutations, for a prevalence of 11.4% (95% CI, 7.0% to 17.7%). The affected genes were *ATM* (two women), *BLM* (one woman), *CDH1* (one woman), *CDKN2A* (one woman), *MLH1* (one woman), *MUTYH* (five women), *NBN* (two women), *PRSS1* (one woman), and *SLX4* (two women). Eleven variants were previously reported in the literature, and five were novel. Consistent with the larger study sample and source population, most of the women carrying pathogenic variants (80%) had a personal history of breast cancer; 67% were non-Hispanic white, 20% were non-Hispanic Asian, and 13% were Hispanic (Table 3).

### Variants of Uncertain Significance

A total of 428 VUS were identified in 39 genes among 175 participants. Per participant, the average number of VUS across all genes was 2.1 (standard deviation, 1.5; Fig 1A). Per gene, the median number of VUS detected across all 198 participants was eight, ranging from zero (*PTEN*, *SMAD4*, *SPINK1*) to 36 (*APC*; Fig 1B). VUS protein effects were as follows: 49 intronic (11.4%), 269 missense (62.9%), 86 silent (20.1%), eight noncoding (1.9%), two in-frame codon loss (0.5%), one in-frame codon gain (0.2%), and 13 unknown (3%). Most of the VUS were novel ( $n = 380$ ; 88.8%); the PolyPhen program predicted that 151 were benign (35.3%), 65 were probably damaging (15.2%), and 50 were possibly damaging (11.7%).<sup>76,77</sup>

### Clinical Interpretation of Pathogenic Variants

Of 16 pathogenic variants in genes other than *BRCA1/2*, we determined that 15 met our criteria for being potentially actionable (Table 3).<sup>69,78,79</sup> One missense variant in *CDKN2A* (NM\_000077.4: c.146T>C) was classified as likely pathogenic based on functional evidence,<sup>80-83</sup> but with conflicting reports<sup>69</sup>; it was therefore considered not actionable.




Fig 1. (A) Frequency of variants of uncertain significance, per participant, across 42 sequenced genes.

### Participant Notification and Clinical Follow-Up

Given the clinical significance of the pathogenic variants deemed potentially actionable, permission was obtained from the Stanford University IRB to contact participants again and offer them the results of their research testing. A genetic counselor (K.E.K.) attempted to call by telephone the 14 women who carried the 15 potentially actionable variants. Of these 14, three were lost to follow-up. Of the 11 women we were able to reach by telephone, 10 accepted a counseling appointment, and one was deceased but her children accepted an appointment. During counseling appointments, participants reviewed and signed a new IRB-approved informed consent document, confirming their willingness to receive study results. The appointments were led by a genetic counselor (K.E.K.) and an oncologist (A.W.K. or J.M.F.); they included an explanation of the results' estimated contribution to cancer risk, CLIA-approved confirmatory testing, and a discussion of risk-adapted screening or prevention options. Six participants (who carried the *ATM*, *BLM*, *CDH1*, *NBN*, and *SLX4* variants) were advised to consider annual breast MRIs because of an estimated doubling of breast cancer risk,<sup>17,18,23,24,34-36,45,46,59-61,84,85</sup> and six participants (who carried the *CDH1*, *MLH1*, and *MUTYH* variants) were advised to consider frequent colonoscopy and/or endoscopic gastroduodenoscopy (once every 1 to 2 years) due to estimated increases in gastrointestinal cancer risk.<sup>1-4,86</sup> One participant (LS294; Table 3) who had triple-negative breast cancer at age 35 years was found to carry a frameshift *MLH1* mutation consistent with Lynch syndrome. Her breast tumor was analyzed by immunohistochemistry and demonstrated absent *MLH1* and *PMS2* expression. She had previously undergone hysterectomy for endometrial carcinoma at age 46 years. After sequencing revealed she had Lynch syndrome, she underwent risk-reducing salpingo-oophorectomy and early colonoscopy, the latter identifying a tubular adenoma that was excised (Fig 2).

## DISCUSSION

We evaluated the clinical performance of a multiple-gene sequencing panel among 198 women meeting evidence-based practice guidelines for *BRCA1/2* testing. We detected 16 pathogenic variants (11.4%; 95% CI, 7.0% to 17.7%) in other genes among women who tested negative for *BRCA1/2* mutations, with 15 variants (10.6%; 95% CI, 6.5% to 16.9%) warranting discussion of more intensive screening or prevention. This is a significant yield of potentially actionable results, comparable to the 5% to 10% probability threshold endorsed by guidelines and payers for *BRCA1/2* and Lynch syndrome testing.<sup>1-3</sup> Up to 10 years after research sample donation, most participants (78.6%) could be reached for results notification, and all accepted confirmatory CLIA-approved testing and counseling. Although further research is required to guide practice, these findings provide an early signal for the clinical relevance of multiple-gene sequencing in cancer-risk assessment.

Multiple-gene sequencing panels have emerged over the last few years, with clinical availability as of 2012.<sup>8,87</sup> However, the United States Supreme Court decision against gene patenting in June 2013 permitted the inclusion of *BRCA1/2* in panels offered by several companies,<sup>87</sup> and a concurrent drop in pricing has provided incentive for the uptake of these new products because a six-gene panel now costs no more than a two-gene test. Owing to absent data on clinical performance, expert opinion statements urge caution in using multiple-gene panels outside a clinical trial.<sup>2,8</sup> Our current study was nested




Fig 1. (B) Variants of uncertain significance (VUS) count, per gene, across 198 participants.

within a Clinical Cancer Genetics practice adherent to evidence-based testing guidelines,<sup>2</sup> and its findings should generalize broadly across clinical settings. Furthermore, its results address real-world challenges of multiple-gene sequencing. Our definition of pathogenic variants as potentially actionable generally follows recommendations of the American College of Medical Genetics (for reporting of incidental findings, although some genes we reported fall outside of these recommendations)<sup>58</sup> and other guideline organizations (for breast MRI screening with a two-fold relative risk increase, which we estimated using published literature on mutation penetrance).<sup>59-61</sup> Notably, there are no data as yet on the risk-benefit ratio of breast MRI screening among patients with pathogenic variants in genes of moderate penetrance (eg, *ATM*, *BLM*). Given the remaining uncertainty in penetrance estimates for such variants, we cannot precisely estimate their contribution to a woman's age-specific cancer risks and, therefore, the optimal breast screening protocol and age of initiation remain unknown. A subjective component is

unavoidable in interpreting unfamiliar variants<sup>11</sup>; other clinicians might make different judgements about patient notification and management. Nonetheless, our experience of results disclosure and risk-adapted intervention may inform future applications of multiple-gene sequencing.

Some of the pathogenic variants we identified would be detected by adherence to current practice guidelines. For example, the participant (LS294) who was found to carry an *MLH1* mutation would now receive Lynch syndrome testing because she had endometrial carcinoma at age 46 years.<sup>1</sup> When she was clinically assessed several years ago, however, Lynch syndrome testing was not routine for early endometrial cancer, and it is still underutilized.<sup>88,89</sup> Moreover, this patient's early triple-negative breast cancer would place *BRCA1/2* testing first in most clinicians' differential diagnoses,<sup>2</sup> such that sequential single-syndrome testing would be slower to provide the correct answer than a multiplex approach. In contrast, other pathogenic variants lack such clear




Fig 2. Pathogenic variant interpretation, participant notification, and clinical follow-up.

guidelines and present significant challenges. One example is the frameshift *SLX4* mutations identified in participants LS347 and LS430. Recently identified as causing Fanconi's Anemia, *SLX4* mutations are predicted to convey a two-fold increase in breast cancer risk that is similar to other pathway components such as *PALB2*. Though some publications support this risk association, *SLX4* mutations appear rare among breast cancer families.<sup>45,46,84</sup> Participants LS347 and LS430 each had a striking family history that included at least three breast cancers diagnosed before age 50 years; we therefore recommended breast MRI screenings, consistent with guidelines for women with increased risk.<sup>59-61</sup> As another example, germline *CDH1* mutations convey substantial risks of gastric and breast cancer in hereditary gastric cancer families<sup>90</sup>; the inadequacy of endoscopic screening leaves prophylactic gastrectomy as the only effective intervention.<sup>6</sup> However, it is unknown whether patients who were found to carry *CDH1* mutations incidentally, without family gastric cancer history, should undergo such life-changing surgery. Because participant LS443's *CDH1* variant has not been reported among gastric cancer patients, we recommended close surveillance rather than gastrectomy. These ambiguous cases illustrate the complexities of multiple-gene sequencing in clinical practice and the potential hazards of unwarranted intervention. As a conservative approach to identified pathogenic variants of uncertain penetrance, we discussed increasing the frequency and/or intensity of cancer screening (Fig 2), but we judged the evidence insufficient to support recommendation of irreversible, invasive interventions such as prophylactic surgery. Another crucial unanswered question is whether testing negative for an identified familial mutation in genes of moderate penetrance (eg, *PALB2*, *CHEK2*) implies that a patient's risk of developing mutation-associated cancers is no greater than that of the general population; we require this missing information to enable risk-appropriate screening. Population-based studies of mutation penetrance and clinical trials of risk-reducing interventions are urgently needed to guide such difficult clinical decisions.

A major concern is the discovery of variants of uncertain significance, which do not contribute to risk assessment and may prompt anxiety and overtreatment. With widespread *BRCA1/2* testing, the prevalence of VUS has declined to an acceptably low rate of 2% to 5%.<sup>91</sup> Predictably, we found that sequencing 42 genes identified VUS in many participants (88%), averaging 2.1 VUS per participant. Our demonstration of this anticipated finding (that sequencing more genes yields more VUS, most of them novel) speaks to nascent efforts toward clinical whole-genome analysis. Moreover, it raises the question of a break-even point: what is the best set and number of genes to maximize information and minimize noise? Consistent with our IRB-approved protocol, we elected not to recontact about VUS, because these results lack practical implications. Outside a study, however, such a decision might conflict with patient autonomy, and the current standard of clinical VUS reporting will likely pertain.<sup>2</sup> Therefore, it is crucial to develop methods for reclassifying VUS quickly and to communicate evolving VUS interpretations according to patients' preferences and understanding. This priority underscores the critical importance of sharing open databases of VUS identified through various genetic sequencing efforts, public and private.

Our study has limitations. The 42 genes that we selected reflect published literature but an optimal multiple-gene panel for routine diagnostic use remains to be defined. We conducted this study in an academic center, within a specialized Clinical Cancer Genetics service that is not universally available. Although participants did not differ significantly from the source population on most measured criteria, it is possible that they had subtle features of personal or family history that suggested greater inherited risk, which might have increased their willingness to donate a research blood sample. Because they were clinically accrued, participants do not represent the entire United States population. Another limitation is the absence of patient-reported preferences and outcomes, which will be a critical consideration in translating next-generation sequencing into practice. Our current results may inform the design of studies that address these important unanswered questions.

To our knowledge, this is the first clinical evaluation of next-generation sequencing among patients referred for breast and ovarian cancer risk assessment. Undoubtedly, multiple-gene sequencing raises many questions about results interpretation and patient counseling. Our study demonstrates an early signal for the clinical relevance of multiple-gene sequencing and provides a strong rationale for future research to define its most effective use.

#### AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

*Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.*

**Employment or Leadership Position:** Emily E. Hare, InVita (C); Yuya Kobayashi, InVita (C); Stephen E. Lincoln, InVita (C); Michele Cargill, InVita (C) **Consultant or Advisory Role:** Uri Ladabaum, Exact Sciences (C); James M. Ford, InVita (U) **Stock Ownership:** Emily E. Hare, InVita; Yuya Kobayashi, InVita; Stephen E. Lincoln, InVita, Illumina; Michele Cargill, InVita **Honoraria:** None **Research Funding:** Allison W. Kurian, InVita; James M. Ford, InVita **Expert Testimony:** None **Patents, Royalties, and Licenses:** None **Other Remuneration:** None

#### AUTHOR CONTRIBUTIONS

**Conception and design:** Allison W. Kurian, Uri Ladabaum, Michele Cargill, James M. Ford

**Financial support:** Allison W. Kurian, James M. Ford

**Administrative support:** Meredith A. Mills, Lisa McPherson

**Provision of study materials or patients:** Allison W. Kurian, Lisa McPherson, James M. Ford

**Collection and assembly of data:** Allison W. Kurian, Emily E. Hare, Meredith A. Mills, Lisa McPherson, Valerie McGuire, Yuya Kobayashi, Stephen E. Lincoln, Michele Cargill, James M. Ford

**Data analysis and interpretation:** Allison W. Kurian, Emily E. Hare, Kerry E. Kingham, Alice S. Whitemore, Uri Ladabaum, Yuya Kobayashi, Stephen E. Lincoln, Michele Cargill, James M. Ford

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

## REFERENCES

1. Burt RW, Cannon JA, David DS, et al: Colorectal Cancer Screening, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, 2013. <http://www.nccn.org>
2. Daly M: Genetic/Familial High-Risk Assessment: Breast and Ovarian, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, 2013. <http://www.nccn.org>
3. Daly MB, Axilbund JE, Buys S, et al: Genetic/familial high-risk assessment: Breast and ovarian. *J Natl Compr Canc Netw* 8:562-594, 2010
4. Ladabaum U, Wang G, Terdiman J, et al: Strategies to identify the Lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis. *Ann Intern Med* 155:69-79, 2011
5. Domchek SM, Friebel TM, Singer CF, et al: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA* 304:967-975, 2010
6. Norton JA, Ham CM, Van Dam J, et al: CDH1 truncating mutations in the E-cadherin gene: An indication for total gastrectomy to treat hereditary diffuse gastric cancer. *Ann Surg* 245:873-879, 2007
7. Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. *J Natl Cancer Inst* 26:1331-1337, 2009
8. Domchek SM, Bradbury A, Garber JE, et al: Multiplex genetic testing for cancer susceptibility: Out on the high wire without a net? *J Clin Oncol* 31:1267-1270, 2013
9. Walsh T, Lee MK, Casadei S, et al: Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. *Proc Natl Acad Sci U S A* 107:12629-12633, 2010
10. Chute CG, Kohane IS: Genomic medicine, health information technology, and patient care. *JAMA* 309:1467-1468, 2013
11. McGuire AL, McCullough LB, Evans JP: The indispensable role of professional judgment in genomic medicine. *JAMA* 309:1465-1466, 2013
12. Tuckson RV, Newcomer L, De Sa JM: Accessing genomic medicine: affordability, diffusion, and disparities. *JAMA* 309:1469-1470, 2013
13. Lowe HJ, Ferris TA, Hernandez PM, et al: STRIDE: An integrated standards-based translational research informatics platform. *AMIA Annu Symp Proc* 2009:391-395, 2009
14. Weber SC, Seto T, Olson C, et al: Oncoshare: Lessons learned from building an integrated multi-institutional database for comparative effectiveness research. *AMIA Annu Symp Proc* 2012:970-978, 2012
15. Kurian AW, Mitani A, Desai M, et al: Breast cancer treatment across health care systems: Linking electronic medical records and state registry data to enable outcomes research. *Cancer* 120:103-111, 2014
16. Redston M, Nathanson KL, Yuan ZQ, et al: The APC11307K allele and breast cancer risk. *Nat Genet* 20:13-14, 1998
17. Renwick A, Thompson D, Seal S, et al: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat Genet* 38:873-875, 2006
18. Broberg K, Huynh E, Schlawicke Engstrom K, et al: Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study. *BMC Cancer* 9:140, 2009
19. Saetrom P, Biesinger J, Li SM, et al: A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. *Cancer Res* 69:7459-7465, 2009
20. Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol* 25:1329-1333, 2007
21. Mavaddat N, Peock S, Frost D, et al: Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. *J Natl Cancer Inst* 105:812-822, 2013
22. Seal S, Thompson D, Renwick A, et al: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. *Nat Genet* 38:1239-1241, 2006
23. Kaurah P, MacMillan A, Boyd N, et al: Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. *JAMA* 297:2360-2372, 2007
24. Pharoah PD, Guilford P, Caldas C: Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. *Gastroenterology* 121:1348-1353, 2001
25. Dean JL, McClendon AK, Hickey TE, et al: Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. *Cell Cycle* 11:2756-2761, 2012
26. Debniak T, Górski B, Huzarski T, et al: A common variant of CDKN2A (p16) predisposes to breast cancer. *J Med Genet* 42:763-765, 2005
27. Jiang L, Zhang C, Li Y, et al: A non-synonymous polymorphism Thr115Met in the EpCAM gene is associated with an increased risk of breast cancer in Chinese population. *Breast Cancer Res Treat* 126:487-495, 2011
28. Barroso E, Pita G, Arias JI, et al: The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features. *Breast Cancer Res Treat* 118:655-660, 2009
29. Kuschel B, Auranen A, McBride S, et al: Variants in DNA double-strand break repair genes and breast cancer susceptibility. *Hum Mol Genet* 11:1399-1407, 2002
30. Lemmens I, Van de Ven WJ, Kas K, et al: Identification of the multiple endocrine neoplasia type 1 (MEN1) gene: The European Consortium on MEN1. *Hum Mol Genet* 6:1177-1183, 1997
31. Neklason DW, Done MW, Sargent NR, et al: Activating mutation in MET oncogene in familial colorectal cancer. *BMC Cancer* 11:424, 2011
32. Win AK, Lindor NM, Young JP, et al: Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. *J Natl Cancer Inst* 104:1363-1372, 2012
33. Rennett G, Lejbkovicz F, Cohen I, et al: MutYH mutation carriers have increased breast cancer risk. *Cancer* 118:1989-1993, 2012
34. Bogdanova N, Feshchenko S, Schürmann P, et al: Nijmegen Breakage Syndrome mutations and risk of breast cancer. *Int J Cancer* 122:802-806, 2008
35. Seemanová E, Jarolim P, Seeman P, et al: Cancer risk of heterozygotes with the NBN founder mutation. *J Natl Cancer Inst* 99:1875-1880, 2007
36. Zhang ZH, Yang LS, Huang F, et al: Current evidence on the relationship between two polymorphisms in the NBS1 gene and breast cancer risk: A meta-analysis. *Asian Pac J Cancer Prev* 13:5375-5379, 2012
37. Rahman N, Seal S, Thompson D, et al: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat Genet* 39:165-167, 2007
38. Pogue-Geile KL, Chen R, Bronner MP, et al: Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. *PLoS Med* 3:e516, 2006
39. Wagner K, Grzybowska E, Butkiewicz D, et al: High-throughput genotyping of a common deletion polymorphism disrupting the TRY6 gene and its association with breast cancer risk. *BMC Genet* 8:41, 2007
40. Lee SJ, Do IG, Lee J, et al: Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. *Target Oncol* 2013
41. Pilarski R, Eng C: Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. *J Med Genet* 41:323-326, 2004
42. Tan MH, Mester JL, Ngewow J, et al: Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 18:400-407, 2012
43. Meindl A, Hellebrand H, Wiek C, et al: Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. *Nat Genet* 42:410-414, 2010
44. Machens A, Lorenz K, Sekulla C, et al: Molecular epidemiology of multiple endocrine neoplasia 2: Implications for RET screening in the new millennium. *Eur J Endocrinol* 168:307-314, 2013
45. Landwehr R, Bogdanova NV, Antonenkova N, et al: Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer. *Breast Cancer Res Treat* 130:1021-1028, 2011
46. Shah S, Kim Y, Ostrovskaya I, et al: Assessment of mutations in hereditary breast cancers. *PLoS One* 8:e66961, 2013
47. Tram E, Ibrahim-Zada I, Briollais L, et al: Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR). *Breast Cancer Res* 13:R77, 2011
48. Soon WW, Miller LD, Black MA, et al: Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. *EMBO Mol Med* 3:451-464, 2011
49. Hearle N, Schumacher V, Menko FH, et al: Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res* 12:3209-3215, 2006
50. Lim W, Olschwang S, Keller JJ, et al: Relative frequency and morphology of cancers in STK11 mutation carriers. *Gastroenterology* 126:1788-1794, 2004
51. Gonzalez KD, Noltner KA, Buzin CH, et al: Beyond Li Fraumeni Syndrome: Clinical characteristics of families with p53 germline mutations. *J Clin Oncol* 27:1250-1256, 2009
52. Kong W, He L, Richards EJ, et al: Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. *Oncogene* 33:679-689, 2014
53. Jacobs K, Paul J, Nilsen G, et al: Accurate detection of small and large copy number events from targeted next-generation sequence data. Presented at the American Society of Human Genetics Annual Meeting, Boston, MA, October 22-26, 2013
54. Richards CS, Bale S, Bellissimo DB, et al: ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. *Genet Med* 10:294-300, 2008
55. Abecasis GR, Auton A, Brooks LD, et al: An integrated map of genetic variation from 1,092 human genomes. *Nature* 491:56-65, 2012

56. Sherry ST, Ward MH, Kholodov M, et al: dbSNP: The NCBI database of genetic variation. *Nucleic Acids Res* 29:308-311, 2001
57. Exome Variant Server: NHLBI GO Exome Sequencing Project (ESP). <http://evs.gs.washington.edu/EVS/>
58. Green RC, Berg JS, Grody WW, et al: ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet Med* 15:565-574, 2013
59. Saslow D, Boetes C, Burke W, et al: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 57:75-89, 2007
60. Mainiero MB, Lourenco A, Mahoney MC, et al: ACR appropriateness criteria breast cancer screening. *J Am Coll Radiol* 10:11-14, 2013
61. Bevers TB, Bonaccio E, Buys SS, et al: Breast Cancer Screening and Diagnosis, Version 2.2013, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, 2013. <http://www.nccn.org>
62. Burt RW: Strategies for colon cancer screening with considerations of cost and access to care. *J Natl Compr Canc Netw* 8:2-5, 2010
63. Robson ME, Storm CD, Weitzel J, et al: American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. *J Clin Oncol* 28:893-901, 2010
64. Buzin CH, Gatti RA, Nguyen VQ, et al: Comprehensive scanning of the ATM gene with DOVAM-S. *Hum Mutat* 21:123-131, 2003
65. Rouleau E, Lefol C, Bourdon V, et al: Quantitative PCR high-resolution melting (qPCR-HRM) curve analysis, a new approach to simultaneously screen point mutations and large rearrangements: Application to MLH1 germline mutations in Lynch syndrome. *Hum Mutat* 30:867-875, 2009
66. Szmola R, Sahin-Tóth M: Uncertainties in the classification of human cationic trypsinogen (PRSS1) variants as hereditary pancreatitis-associated mutations. *J Med Genet* 47:348-350, 2010
67. Ali M, Kim H, Cleary S, et al: Characterization of mutant MUTYH proteins associated with familial colorectal cancer. *Gastroenterology* 135:499-507, 2008
68. Eliason K, Hendrickson BC, Judkins T, et al: The potential for increased clinical sensitivity in genetic testing for polyposis colorectal cancer through the analysis of MYH mutations in North American patients. *J Med Genet* 42:95-96, 2005
69. Lai G, Liu L, Hogg D, et al: Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. *Genes Chromosomes Cancer* 27:358-361, 2000
70. Bai H, Jones S, Guan X, et al: Functional characterization of two human MutY homolog (hMYH) missense mutations (R227W and V232F) that lie within the putative hMSH6 binding domain and are associated with hMYH polyposis. *Nucleic Acids Res* 33:597-604, 2005
71. Sieber OM, Lipton L, Crabtree M, et al: Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. *N Engl J Med* 348:791-799, 2003
72. Seemanova E, Sperling K, Neitzel H, et al: Nijmegen breakage syndrome (NBS) with neurological abnormalities and without chromosomal instability. *J Med Genet* 43:218-224, 2006
73. Suriano G, Oliveira C, Ferreira P, et al: Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. *Hum Mol Genet* 12:575-582, 2003
74. McConville CM, Stankovic T, Byrd PJ, et al: Mutations associated with variant phenotypes in ataxia-telangiectasia. *Am J Hum Genet* 59:320-330, 1996
75. Mitui M, Nahas SA, Du LT, et al: Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: Mutations with increased cancer risk. *Hum Mutat* 30:12-21, 2009
76. Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs: Server and survey. *Nucleic Acids Res* 30:3894-3900, 2002
77. Sunyaev S, Ramensky V, Koch I, et al: Prediction of deleterious human alleles. *Hum Mol Genet* 10:591-597, 2001
78. Kim JC, Roh SA, Koo KH, et al: Genotyping possible polymorphic variants of human mismatch repair genes in healthy Korean individuals and sporadic colorectal cancer patients. *Fam Cancer* 3:129-137, 2004
79. Kim YM, Choe CG, Cho SK, et al: Three novel germline mutations in MLH1 and MSH2 in families with Lynch syndrome living on Jeju island, Korea. *BMB Rep* 43:693-697, 2010
80. Miller PJ, Duraisamy S, Newell JA, et al: Classifying variants of CDKN2A using computational and laboratory studies. *Hum Mutat* 32:900-911, 2011
81. Ranade K, Hussussian CJ, Sikorski RS, et al: Mutations associated with familial melanoma impair p16INK4 function. *Nat Genet* 10:114-116, 1995
82. Reymond A, Brent R: p16 proteins from melanoma-prone families are deficient in binding to Cdk4. *Oncogene* 11:1173-1178, 1995
83. Walker GJ, Gabrielli BG, Castellano M, et al: Functional reassessment of P16 variants using a transfection-based assay. *Int J Cancer* 82:305-312, 1999
84. Bakker JL, van Mil SE, Crossan G, et al: Analysis of the novel fanconi anemia gene SLX4/FANCP in familial breast cancer cases. *Hum Mutat* 34:70-73, 2013
85. Cybulski KE, Howlett NG: FANCP/SLX4: A Swiss army knife of DNA interstrand crosslink repair. *Cell Cycle* 10:1757-1763, 2011
86. Morak M, Laner A, Bacher U, et al: MUTYH-associated polyposis: Variability of the clinical phenotype in patients with biallelic and monoallelic MUTYH mutations and report on novel mutations. *Clin Genet* 78:353-363, 2010
87. Offit K, Bradbury A, Storm C, et al: Gene patents and personalized cancer care: Impact of the myriad case on clinical oncology. *J Clin Oncol* 31:2743-2748, 2013
88. Backes FJ, Mitchell E, Hampel H, et al: Endometrial cancer patients and compliance with genetic counseling: Room for improvement. *Gynecol Oncol* 123:532-536, 2011
89. Kalloger SE, Allo G, Mulligan AM, et al: Use of mismatch repair immunohistochemistry and microsatellite instability testing: Exploring Canadian practices. *Am J Surg Pathol* 36:560-569, 2012
90. Chun N, Ford JM: Genetic testing by cancer site: Stomach. *Cancer J* 18:355-363, 2012
91. Hall MJ, Reid JE, Burbidge LA, et al: BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. *Cancer* 115:2222-2233, 2009

## GLOSSARY TERMS

**BRCA1:** a tumor suppressor gene known to play a role in repairing DNA breaks. Mutations in this gene are associated with increased risks of developing breast or ovarian cancer.

**BRCA2:** a tumor suppressor gene whose protein product is involved in repairing chromosomal damage. Although structurally different from BRCA1, BRCA2 has cellular functions similar to BRCA1. BRCA2 binds to RAD51 to fix DNA breaks caused by irradiation and other environmental agents. Also known as the breast cancer 2 early onset gene.

**CDH1:** cadherin 1 gene. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid, and ovarian cancers.

**Lynch syndrome:** hereditary nonpolyposis colorectal cancer (HNPCC). A cancer syndrome characterized by Henry T. Lynch in 1966, this genetic condition has a high risk of colon cancer as well as other cancers including endometrial, ovary, stomach, small intestine, hepatobiliary tract, upper urinary tract, brain, and skin.

**MLH1 (MutL homolog 1):** a DNA mismatch repair enzyme. MLH1 is responsible for overall fidelity of DNA replication.